MSD secures victory before English court
20-10-2020
Australian court issues mixed vaccine patent ruling
15-10-2020
Biogen loses another battle over MS drug patent
21-09-2020
Fed Circuit rejects Biogen’s plea in MS drug dispute
23-04-2020
Repelsteeltje / Shutterstock.com
The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis (MS) drug patent, in a defeat for biotech company Biogen.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, Merck KGaA, Biogen, EMD Serono, Federal Circuit, multiple sclerosis, patent infringement, patent invalidation
